000 02388cam a2200349 a 4500
003 EG-GiCUC
005 20250223031527.0
008 160709s2015 ua h f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.01.Ph.D.2015.Ra.U
100 0 _aRania Mohamed Ali Shoeib
245 1 0 _aUltrasound guided peribulbar block versus SubTenon{u2019}s block in patients on continuos :
_bWarfarin undergoing cataract surgery /
_cRania Mohamed Ali Shoeib ; Supervised Sherry Nabil Rizk , Mohamed Ali Marzouk , Mona Raafat Fahim
246 1 5 _aمقارنة تخدير حول مقلة العين بمساعدة الموجات فوق الصوتية و التخدير تحت طبقة ثنون فى المرضى المستمرين فى تعاطى عقار ورفارين و يقومون باجراء عمليات مياة بيضاء
260 _aCairo :
_bRania Mohamed Ali Shoeib ,
_c2015
300 _a90 P. :
_bfacsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia
520 _aOral anticoagulant therapy is used commonly in elderly AF patients requiring cataract surgery. A decision has to be made whether to continue anticoagulants therapy or not. On one hand, continuing such treatments is frequently thought to increase both the risk for surgical bleeding and the risk of haematoma from eye block puncture. On the other hand, discontinuing those therapies may unacceptably increase the risk for thrombosis in at-risk patients, for example, those with atrial fibrillation, non-tissue prosthetic heart valves, carotid stenosis or coronary drug-eluting stents. These risks include cerebral ischemic stroke, myocardial infarction and death. In fact, cataract surgery is considered a {u2018}bloodless{u2019} procedure. From all the studies quoted we can say that warfarin can be continued safely in AF patients undergoing cataract surgery
530 _aIssued also as CD
653 4 _aCataract Surgery
653 4 _aUltrasound guided
653 4 _aWarfarin
700 0 _aMohamed Ali Marzouk ,
_eSupervisor
700 0 _aMona Raafat Fahim ,
_eSupervisor
700 0 _aSherry Nabil Rizk ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c57099
_d57099